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Abstract Approximately, 7 % of all breast cancers (BC)
and 11–15 % of ovarian cancers (OC) are associated with
inherited predisposition, mainly related to germline muta-
tions in high penetrance BRCA1/2 genes. Clinical criteria
for genetic testing are based on personal and family history
to estimate a minimum 10 % detection rate. Selection
criteria are evolving according to new advances in this field
and the clinical utility of genetic testing. Multiplex panel
testing carries its own challenges and we recommend
inclusion of genes with clinical utility. We recommend
screening with annual mammography from age 30 and
breast MRI from age 25 for BRCA1 and BRCA2 mutation
carriers. Bilateral salpingo-oophorectomy should be
offered to women with a BRCA1 or BRCA2 mutation,
between 35 and 40 years and after completion of child-
bearing, or individualise based on the earliest age of
ovarian cancer diagnosed in the family. Bilateral risk-re-
ducing mastectomy is an option for healthy BRCA1 and
BRCA2 mutation carriers, as well as contralateral mas-
tectomy for young patients with a prior BC diagnosis.
BRCA genetic testing in patients with BC and OC may
influence their locoregional and systemic treatment.
Keywords Hereditary breast and ovarian cancer 
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Hereditary breast and ovarian cancer syndrome
(HBOC): introduction
Approximately, 7 % of all breast cancers (BC) and
11–15 % of ovarian cancers (OC) are associated with
inherited predisposition, mainly related to germline muta-
tions in high penetrance BRCA1/2 genes. A meta-analysis
reports mean cumulative BC risk at age 70 years of 57 %
(95 % CI 47–66) for BRCA1 and 49 % (95 % CI 40–57)
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for BRCA2 mutation carriers; and OC risk of 40 % (95 %
CI 35–46) for BRCA1 and 18 % (95 % CI 13–23) for
BRCA2 mutation carriers [1, 2].
Advances in sequencing technologies make massive
parallel sequencing more feasible and afford testing for
other hereditary predisposition genes assigned to high BC
risk (TP53, PALB2, PTEN), moderate BC risk (CHEK2,
ATM, NF1, NBN), elevated, but imprecise BC risk (CDH1,
STK11) and OC risk (MMR genes, RAD51D, BRIP1) [3].
HBOC families associated to BRCA1 or BRCA2 germ-
line mutations present an autosomal dominant hereditary
pattern, with early ages of cancer onset, bilaterality and
male breast cancer. BRCA1-associated BC usually have a
higher histological grade and a triple-negative basal phe-
notype. OC in BRCA1 and BRCA2 mutation carriers are
high-grade serous adenocarcinoma with intraepithelial
infiltrates, lymphocytic atypia and abundant mitoses.
Criteria for BRCA genetic testing
We recommend genetic counselling pre- and post-germline
genetic testing. Genetic counselling is a process that
guarantees a discussion about the benefits and limitations
of genetic testing, provides risk estimates of developing
cancer, recommendations for early detection and preven-
tive measures, information about reproductive options and
support for psychological well-being.
Clinical criteria for genetic testing are based on personal
and family history to estimate a minimum 10 % detection
rate [4, 5]. Hence, selection criteria are evolving according to
new advances in this field and the clinical utility of genetic
testing (Table 1). Multiplex panel testing carries its own
challenges and we recommend inclusion of genes with
clinical utility. If multiplex testing is considered for HBOC,
we recommend including TP53, PALB2, BRIP1, RAD51C
and RAD51D [6]. Other genes like CDH1 and PTEN might
be offered based on familial phenotype (bilateral lobular
BC\ 50, Cowden-like features) or when specific criteria for
the hereditary cancer syndrome are present.
Surveillance and strategies for early detection
of cancer in mutation carriers
Early detection of breast cancer aims to reduce morbidity
and mortality. An individual patient data meta-analysis of
high-quality observational studies shows that the use of
breast MRI as an adjunct to mammography significantly
increases the sensitivity of screening in women with
BRCA1 and BRCA2 mutations as compared with mam-
mography alone (93.4 vs 39.6 %; p\ 0.001), whereas
specificity is significantly reduced (80.3 vs 93.6 %;
p = 0.0016) [7]. Although a survival benefit from breast
MRI in these women has not robustly been proven, a clear
trend towards improved metastasis-free survival has been
reported [8]. Therefore, we recommend annual mammog-
raphy and breast MRI screening for BRCA1 and BRCA2
mutation carriers (IIA).
The appropriateness of imaging scheduling is still con-
troversial. The pooled-data analysis includes women
between 30 and 70 years, with MRI and mammography
being performed within 1–2 months from each other [7]. In
addition, radiation-induced breast cancer is a potential
concern in women younger than 30 years, who also present
denser breast tissue which hampers a good visualisation on
mammograms. So, we recommend an annual breast MRI
from age 25, with a synchronous annual mammography
added after age 30 until age 70 (Table 2).
There are limited data to support breast imaging in men,
but we recommend considering mammography at age
40 years, especially if gynaecomastia or in BRCA2 carriers
(IIIC).
Women with a BRCA1 or BRCA2 mutation who have
not chosen prophylactic salpingo-oophorectomy may fol-
low determination of Ca125 and transvaginal ultrasound
since age 35 (IIC), but they should be informed that early
detection of ovarian cancer is not guaranteed.
Screening for prostate cancer at age 40 is recommended
for males with a BRCA2 mutation, due to the increased risk
and poor survival outcomes, and should be individualised
for BRCA1 male mutation carriers [9] (IIB).
Screening for colorectal cancer with annual FIT or
colonoscopy every 5 years beginning at 40 should be
encouraged especially in BRCA1 carriers (IIIC).
Consider individualised screening for pancreatic cancer
and melanoma, based on family history.
Risk-reducing surgery
Bilateral salpingo-oophorectomy
The absence of reliable methods for early detection and the
poor prognosis associated with advanced ovarian cancer
have supported the recommendation of bilateral risk
reduction salpingo-oophorectomy (RRSO) after comple-
tion of childbearing in women with BRCA1 or BRCA2
mutation [10]. Preventive oophorectomy was associated
with an 80 % reduction in the risk of ovarian, fallopian
tube or peritoneal cancer in BRCA1 or BRCA2 carriers and
a 77 % reduction in all-cause mortality [10, 11].
A 1–4.3 % residual risk of a primary peritoneal carci-
noma has been reported in some studies [12]. A meta-
analysis involving 10 studies showed an approximately
80 % reduction in the risk of ovarian or fallopian cancer
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following RRSO. The meta-analyses also found that RRSO
reduces the breast cancer risk by approximately 50 % [12].
Bilateral salpingo-oophorectomy should be offered to
women with a BRCA1 or BRCA2 mutation, between 35 and
40 years and after completion of childbearing, or individ-
ualised based on the earliest age of ovarian cancer diag-
nosed in the family (II,A).
Given that short-term HT seems to improve quality of
life and does not seem to increase risk of BC in healthy
BRCA mutation carriers after bilateral prophylactic
oophorectomy [13], short-term and low-dose hormone
therapy in oophorectomised BRCA mutation carriers
without a personal history of breast cancer might be con-
sidered (II,B).
Prophylactic mastectomy
Retrospective analyses have indicated that bilateral risk
reduction mastectomy (BRRM) decreases breast cancer
risk by at least 90 % in BRCA1 and BRCA2 mutation
carries [10, 14].
In healthy BRCA1 or BRCA2 mutation carriers, BRRM
reduces BC risk when compared to surveillance, while longer
follow-up is warranted to confirm survival benefits [15].
Table 1 Selection criteria for
BRCA genetic testing
Regardless of family history:
Women with synchronous or metachronous BC and OC
BC B35 years (or BC B40 years in case of uninformative familya)
Bilateral BC (the first diagnosed B40 years)
Triple-negative BC B50 years
High-grade epithelial non-mucinous OC (or fallopian tube or primary peritoneal cancer)
2 or more first degree relativesb with any combination of the following high-risk features:
Bilateral BC ? another BC\50 years
Male breast cancer
BC ? OC
Two cases of BC diagnosed before age 50 years
3 or more direct relativesb with BC and/or OC:
C3 BC ± OC
BC breast cancer, OC ovarian cancer
a Less than 2 women who have lived until age 45 or older in each side of the family







Breast self awareness Starting at age 18 years IIA
Clinical breast exam every
6–12 months
Starting at age 25 years IIA
Annual breast MRI 25–70 years IIA
Annual mammogram 30–35 to 75 years IIA




Breast self awareness Starting at age 35 years IIIC
Annual clinical breast exam Starting at age 35 years IIIC
Basal mammogram 40 years (individualised) IIIC
Annual Prostate Cancer screening Starting at age 40 years IIIB
Men and women
Pancreatic and melanoma Consider individualised screening based on




Starting at 40 years or younger if family
history
IIB
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In a recent prospective analysis, contralateral RRM was
found to be associated with improved overall survival in
BRCA1 or BRCA2 mutation carriers with a prior primary
breast cancer (PBC). Survival benefit was especially seen
in young patients (\40 years), with grade 1/2 differentia-
tion and/or no triple-negative phenotype, and in patients
not treated with adjuvant chemotherapy [16].
Bilateral risk-reducing mastectomy is an option for
healthy BRCA1 and BRCA2 mutation carriers, as well as
contralateral mastectomy for young patients with a prior
BC diagnosis (II,B).
Chemoprevention
Several case–control studies in BRCA mutation carriers
with breast cancer show that the use of tamoxifen protects
against contralateral breast cancer [17].
Adjuvant tamoxifen reduces the risk of a second breast
cancer in patients with a BRCA mutation and a prior BC
(II,A).
In the Breast Cancer Prevention Trial, healthy women
with a BRCA2 mutation receiving tamoxifen had a reduc-
tion of breast cancer by 62 %, an effect not seen among
those with a BRCA1 mutation, but the overall number of
individuals was very small. There are no other chemopre-
vention trials in BRCA mutation carriers, except for an
ongoing randomised clinical trial by the French Federation
of Cancer Centers investigating the preventive effect of
letrozole in postmenopausal women with a BRCA1 or
BRCA2 mutation [18]. There is no demonstrated benefit for
primary chemoprevention of breast cancer in BRCA1 or
BRCA2 mutation carriers (I,A).
In a recent meta-analysis of case–control studies in
BRCA1 and BRCA2 mutation carriers, a significant 50 %
risk reduction of ovarian cancer was associated with the
past use of combined oral contraceptives [19]. Neverthe-
less, there are conflicting results on the effect of oral
contraceptive use on breast cancer risk in BRCA mutations
carriers. A recent case–control study in BRCA1 carriers
found that oral contraceptives use before age 25 increases
the risk of early onset breast cancer among BRCA1 muta-
tion carriers and the risk increases with duration of use
[20].
Use of oral contraceptives protects against ovarian
cancer (II,B), but caution should be used when considering
them in mutation carriers because of the conflicting results
on their effect on breast cancer risk. BRCA1 carriers should
be advised to avoid oral contraceptive use if the purpose is
to prevent ovarian cancer before the age of 25 (IIB).
Treatment strategies in BRCA carriers
Breast conservative surgery in patients with early stage BC
is associated with high rates of second ipsilateral recur-
rences, but no differences in BC-specific survival com-
pared to mastectomy. Mutation carriers have a higher risk
of contralateral BC than sporadic BC patients. Therefore,
BRCA genetic testing in patients with early stage BC may
influence their locoregional treatment (III,A).
Platinum salts have shown a high pathological complete
response in the neoadjuvant setting among patients with
breast cancer and a BRCA1 or BRCA2 germline mutation
[21, 22]. In the metastatic setting, carboplatin has shown a
statistically clinical benefit when compared to docetaxel
among BRCA mutation carriers [23]. Randomised phase 3
trials of PARPi for patients with BRCA-associated BC are
ongoing.
Platinum salts might be considered in the neoadjuvant
setting (I,C), and in the metastatic setting among patients
with BC and a BRCA mutation (I,A) (Table 3).
Retrospective studies have shown an improved prog-
nosis, higher response rates and longer treatment-free
intervals between relapses in patients with a BRCA1/2-
mutated ovarian cancer treated with platinum-containing
Table 3 Risk reduction and therapeutic strategies in BRCA mutation carriers
Adjuvant tamoxifen reduces the risk of contralateral breast cancer (IIA)
Benefit of tamoxifen for primary prevention is not demonstrated in BRCA mutation carriers (IA)
Oral contraceptives protect against ovarian cancer (IIB), but caution should be used when considering use of oral contraceptives in mutation
carriers because the conflicting results on their effect on breast cancer risk
Bilateral Salpingo-oophorectomy should be recommended between 35 and 40 years and upon completion of child bearing (IA)
Bilateral prophylactic mastectomy reduces the risk of breast cancer by at least 90 % (IIB), and is an option for healthy BRCA1 and BRCA2
mutation carriers, as well as contralateral mastectomy for young patients with a prior breast cancer diagnosis (IIB)
Platinum salts might be considered in neoadjuvant setting (IC) and in the metastatic setting (IA)
PARPi are recommended as maintenance therapy in patients with relapsed platinum-sensitive high-grade serous ovarian cancer (IA)
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regimens compared with sporadic ovarian cancer patients
[24]. These tumours also show high sensitivity to anthra-
cyclines [25]. Poly(ADP-ribose) polymerase (PARP) inhi-
bitors lead to synthetic lethality in HR-deficient cells and
they are active drugs in patients with BRCA1 or BRCA2-
mutated ovarian cancer. Olaparib is the first EMA-ap-
proved PARPi as a maintenance therapy in patients with
relapsed platinum-sensitive high-grade serous ovarian
cancer [26].
Alkylating and DNA-damaging agents are recom-
mended for patients with ovarian cancer (I,A). PARPi are
recommended as maintenance therapy in patients with
relapsed platinum-sensitive high-grade serous ovarian
cancer (I,A).
Management of women without identified BRCA
mutations (BRCAX)
Women with a breast cancer family history and an incon-
clusive BRCA genetic test have a higher risk of developing
breast cancer (RR = 3.94, 95 % CI 3.09–5.02), but no
increased ovarian cancer risk [27].
Monitoring of breast cancer for these women should
include breast awareness from age 18 (III,B), clinical
breast examination every 6 months since age 25
(III,B) and annual mammography from age 40 or 10 years
before the youngest case of breast cancer in the family
(II,B). Add an annual breast MRI from age 25 when the
BC lifetime risk is over 20–25 % (IIB). The risk will be
determined by predictive models as BRCAPRO, BOADI-
CEA or Tyrer-Cuzyck [28] (Table 4).
Surveillance with ultrasound should not routinely be
offered to women at moderate or high risk of BC, but it
might be considered when MRI surveillance is not suit-
able or when results of mammography or MRI are difficult
to interpret.
Gynaecological monitoring is not necessary in families
with no family history of ovarian carcinoma. If family
history of ovarian carcinoma exists, the medical manage-
ment should be individualised.
Tamoxifen (pre- and post-menopausal women) and
raloxifene (only postmenopausal women) are recom-
mended for breast cancer chemoprevention for a maximum
of 5 years among women at high risk according to the
NICE guidelines (http://www.nice.org.uk/guidance/cg164),
and are approved by the FDA for this purpose. Both drugs
can be considered for breast cancer chemoprevention in
women[35 years at high risk (I,A).
Other hereditary breast cancer syndromes
Other breast cancer susceptibility genes have been identi-
fied as TP53, PTEN and PALB2 as high penetrance, and
CHEK2, BRIP1, ATM, BARD1, NBN, RAD51C with lower
penetrance [2]. CDH1 is considered high-penetrance gene
for diffuse gastric cancer, but the BC risk has not been fully
established.
TP53 is involved in only 1 % of hereditary breast cancer
cases. It is associated with a high lifetime risk of cancer,
most diagnosed at young age as bone and soft tissue sar-
coma, premenopausal breast cancer, acute leukaemia,
colon cancer, adrenal cortex carcinoma, brain tumours and
ovarian cancer.
Breast screening must begin at age 20 years with annual
MRI and add annual mammogram at age 30. The option of
risk-reducing mastectomy should be discussed in TP53
mutation carriers (II,A).
Cowden syndrome (PTEN) is a rare hereditary cancer
syndrome. The incidence is 1 in 200.000. The estimated
cumulative lifetime risk for breast cancer is 67–85 % and
patients may develop cancers of thyroid, endometrial,
colorectal, renal and melanoma. Hamartomatous lesions
are characteristic manifestations of this syndrome.
Breast screening consists of annual mammogram and
breast MRI beginning at age 30. The option of risk-re-
ducing mastectomy and hysterectomy should be discussed
(II,A).
Germline mutations in CDH1 are associated with
Hereditary Diffuse Gastric Cancer Syndrome [29]. Women
have a cumulative lifetime risk of lobular breast cancer of
23–68 %. CDH1 germline mutations can also be found in
the absence of DG cancer, especially in families with[3
lobular BC or bilateral lobular cancer before age 50.
Annual mammography and breast MRI from the age of
35 is recommended in CDH1 mutation carriers (II,A).
The breast cancer risk associated with mutations in the
lower-penetrance genes is currently imprecise. Clinical
management is case-by-case depending on the family
Table 4 Surveillance in
women from high-risk families
without identified BRCA
mutations
Breast self awareness starting at age 18 (IIIB)
Semiannual clinical breast exam starting at age 25 (IIIB)
Annual mammogram starting at age 40–70, or 10 years before the youngest age of BC in the family (IIB)
If lifetime risk[20–25 %, consider annual breast MRI starting at age 25 (IIB)
Ovarian early detection is not necessary in women with no family history of ovarian carcinoma (IIA)
960 Clin Transl Oncol (2015) 17:956–961
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history [30]. The use of multigene panel testing will
increase the diagnosis of such mutations, but more clinical
research is needed to learn about their precise clinical
meaning.
Evidence levels To assign a level of evidence and a
grade of recommendation to the different statements of this
guideline, it was decided to use the Infectious Diseases
Society of America-US Public Health Service Grading
System for Ranking Recommendations in Clinical Guide-
lines to determine the quality of evidence and strength of
recommendation in each of the consensus recommenda-
tions [31].
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